First Author: M.Kawamura JAPAN
Co Author(s): Y. Hirano M. Yoshida T. Mizutani K. Sugitani Y. Ogura
Back to previous
To report the 6-month results of 1 initial intravitreal ranibizumab injection (IVR) followed by pro re nata (PRN) dosing (1+PRN) in patients with branch retinal vein occlusion (BRVO).
Nagoya City University Hospital, Prospective, Interventional study.
Patients who had macular edema following BRVO and included the following criteria were enrolled; 18 years old, 20 letters the best-corrected visual acuity (BCVA) 77 letters, 250 μm in central retinal thickness (CRT), and agreement with the current study. One initial IVR was performed followed by monthly visit and PRN dosing. The primary efficacy outcome measure was mean change from baseline BCVA at month 6. The secondary outcomes included other parameters of visual function, mean change of CRT from baseline, and number of injections.
Twenty-one patients (7 men and 14 women) were enrolled from March 2014 through April 2017 at Nagoya City University Hospital. The mean age was 66.8 ± 10.7 years (mean ± standard deviation). The mean period from disease symptoms to initial injection was 2.39 ± 3.61 months. Baseline ETDRS letters and the CRT were 63.0 ± 12.7 letters and 513 ± 118 μm, respectively. The mean ETDRS gain was 14.5 ± 10.5 letters and the mean CRT reduction was 234 ± 121 μm. The percentage of patients who had Snellen BCVA of ≧ 0.5 and 1.0 at month 6 was 95.2 and 66.7 %. The percentage of patients who gained 15 letters in BCVA at month 6 was 47.6 %. The mean number of IVR was 4.04. No adverse side effects were observed.
One plus PRN regimen with IVR in the current study was not only comparable to previous studies, but also superior in high rate of patients who had Snellen BCVA of 0.5 and 1.0.